Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read MoreMany biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. A look at what 2024 might
Read MoreShares of other biotech companies developing ADCs, which are among the hottest areas in the pharmaceutical industry, jumped on the
Read MoreThe biotech sector is hot on Wall Street right now. Here are some of Bank of America's favorite stocks going
Read More